Kassen agreement on hepatitis C agents

SHI and manufacturers agree on reimbursement amount for hepatitis C funds

02/13/2015

After seven months of negotiations, the statutory health insurance agreed with the US pharmaceutical company Gilead Sciences on a refund amount for the new hepatitis C drug Sovaldi.

Reimbursement amount for hepatitis C funds set
As reported by the German Association of Statutory Health Insurance Funds (GKV) on Thursday in Berlin, an agreement was reached on the reimbursement amount for the new hepatitis C drug Sovaldi. Accordingly, retroactively to January 23, 2015, a reimbursement amount of around € 14,520 per package applies. For a twelve-week therapy, around 43,500 euros will be reimbursed. So far, minimum prices of 60,000 euros were incurred for the therapy.

Negotiations on the reimbursement amount under the Market Restructuring Act were based on the differentiated decision of the Joint Federal Committee of 17 July 2014. „In around 5 percent of patients, the presence of sofosbuvir in the treatment of chronic hepatitis C is an indication of significant added benefit, approximately 35 percent of patients were rated as having a minor added benefit, and about 60 percent of patients considered added benefit busy“, informs the top association. (Ag)

Image: I-vista